Abstract
Lung cancer is a good candidate for screening. The NLST trial demonstrated that annual low-dose CT-scan in a high risk population of smokers reduced specific mortality by 20% and overall mortality by 6.7%.Current position of lung cancer screening in France and worldwide is presented in this review.In France, the topic is dominated by french heath autorithies skepticism. Worldwide there are deep differences: US and Canada have iplemented lung cancer screening in routine while Europe still waiting for NELSON results and pooled analysis of european trials.In practice, interval between two low-dose CT-scan ay be delayed at 2 years (but no more), in particular among individuals who have a negative CT-scan. Biomarkers and risk-prediction scores are clearly very interesting perpectives but need prospective validation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
